CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹936 Cr | ₹634 Cr | ₹567 Cr | ₹743 Cr | ₹622 Cr |
What is the latest Contingent Liabilities ratio of CIPLA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹936 Cr |
| Mar2024 | ₹634 Cr |
| Mar2023 | ₹567 Cr |
| Mar2022 | ₹743 Cr |
| Mar2021 | ₹622 Cr |
How is Contingent Liabilities of CIPLA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹936 Cr | 47.65 | |
| Mar2024 | ₹634 Cr | 11.90 | |
| Mar2023 | ₹567 Cr | -23.73 | |
| Mar2022 | ₹743 Cr | 19.41 | |
| Mar2021 | ₹622 Cr | - | |
Compare Contingent Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹112,926.4 Cr | -4.7% | -6.8% | -0.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹400,497.0 Cr | -3.5% | -6.4% | -2.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹165,492.0 Cr | -5.8% | -1.6% | 10.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹136,013.0 Cr | 1.4% | 7% | 23.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,115.0 Cr | -2.8% | -8.1% | -11.1% | Stock Analytics | |
| MANKIND PHARMA | ₹89,832.6 Cr | -1.1% | 3.3% | -13.4% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -4.7% |
-6.8% |
-0.3% |
| SENSEX | -0.7% |
-1.9% |
8% |
You may also like the below Video Courses